Latest & greatest articles for infection

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infection or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infection and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infection

1. Transmission of SARS-CoV-2: implications for infection prevention precautions

or singing; in these circumstances, respiratory droplets that include virus can reach the mouth, nose or eyes of a susceptible person and can result in infection. Indirect contact transmission involving contact of a susceptible host with a contaminated object or surface (fomite transmission) may also be possible (see below). Airborne transmission Airborne transmission is defined as the spread of an infectious agent caused by the dissemination of droplet nuclei (aerosols) that remain infectious when (...) within the recipient. However, the proportion of exhaled droplet nuclei or of respiratory droplets that evaporate to generate aerosols, and the infectious dose of viable SARS-CoV-2 required to cause infection in another person are not known, but it has been studied for other respiratory viruses.(17) One experimental study quantified the amount of droplets of various sizes that remain airborne during normal speech. However, the authors acknowledge that this relies on the independent action hypothesis

2020 WHO Coronavirus disease (COVID-19) Pandemic

2. Infection prevention and control for the safe management of a dead body in the context of COVID-19

of deceased persons infected with COVID-19 should be consistent with those that apply to the autopsies of people who have died of an acute respiratory illness or other infectious diseases. (7,11- 13) If the person died of COVID-19 while he or she was infectious, the lungs and other organs may still contain live virus.(11). If the body of a person with suspected or confirmed COVID-19 is selected for autopsy, health-care facilities must ensure that safety measures are in place to protect those performing (...) Infection prevention and control for the safe management of a dead body in the context of COVID-19 -1- Infection prevention and control for the safe management of a dead body in the context of COVID-19 Interim guidance 4 September 2020 Background This interim guidance is designed for individuals who tend to the bodies of persons who have died of suspected or confirmed coronavirus disease 2019 (COVID-19). Potential users include managers of health-care facilities and mortuaries, as well

2020 WHO Coronavirus disease (COVID-19) Pandemic

3. Management of suspected bacterial lower urinary tract infection in adult women

use, patients should be thoroughly evaluated for the source of signs and symptoms before attributing them to the urinary tract. The presence of bacteria in the urine of catheterised patients is common and inevitable but ASB does not necessarily indicate presence of infection. 6 | Catheter-associated lower urinary tract infection in women35 Management of suspected bacterial lower urinary tract infection in adult women The following statements are reproduced, with permission, from The Infectious (...) Management of suspected bacterial lower urinary tract infection in adult women Management of suspected bacterial lower urinary tract infection in adult women A national clinical guideline September 2020 SIGN160Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta-analyses, systematic reviews

2020 SIGN

4. Probable healthcare associated infections in England

Probable healthcare associated infections in England Probable healthcare associated infections in England - CEBM CEBM The Centre for Evidence-Based Medicine develops, promotes and disseminates better evidence for healthcare. Navigate this website Probable healthcare associated infections in England October 9, 2020 Daniel Howdon, Jason Oke, Tom Jefferson, Carl Heneghan Recent days have seen an apparent rise in the proportion of patients newly admitted in hospital with COVID-19 that represent (...) probable healthcare-associated infections (HCAIs), with these comprising 18% of all new hospital cases on 6 October. This is most apparent in the North West of England, where HCAIs made up 24% of all patients on this date. NHS England produces a daily update on new hospitalisations by region. As of 22 September, the from situation reports on the number of hospital admissions and diagnoses for COVID-19 were made available. This contains several data series which categorise patients based on whether

2020 Oxford COVID-19 Evidence Service

5. Coronavirus (COVID-19) infection and pregnancy

Coronavirus (COVID-19) infection and pregnancy 1 Information for healthcare professionals Version 12: Published Wednesday 14 October 2020 Coronavirus (COVID-19) Infection in Pregnancy2 Contents Summary of updates 3–5 1 Purpose and scope 6–12 2 Antenatal care during the COVID-19 pandemic 13–22 3 Venous thromboembolism prevention 23–25 4 Labour and birth during the COVID-19 pandemic 26–35 5 Managing clinical deterioration during the COVID-19 pandemic 36–42 6 Postnatal care 43–47 7 Acknowledgments (...) partners and other supportive adults has been published by the NHS, and should be followed as far as possible.5 12 14.10.20 4.6 Water birth: Supporting statement updated to reflect evidence review by the UK Infection Prevention and Control Cell. 12 14.10.20 6.3 Postnatal care: Recommendation revised to clarify that postnatal women who have tested positive for COVID-19, while required to isolate along with their households for 14 days, should still receive necessary in- person postnatal care. 12

2020 Royal College of Obstetricians and Gynaecologists

6. Delafloxacin (Quofenix) - for the treatment of acute bacterial skin and skin structure infections (ABSSSI)

Delafloxacin (Quofenix) - for the treatment of acute bacterial skin and skin structure infections (ABSSSI) delafloxacin (Quofenix®) - All Wales Medicines Strategy Group Opens in new window Cymraeg Search Search Cymraeg Menu Search › › › delafloxacin (Quofenix®) Following non-submission AWMSG advice Status: Not endorsed (Statement of Advice) In the absence of a submission from the holder of the marketing authorisation, delafloxacin (Quofenix®) cannot be endorsed for use within NHS Wales (...) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections. Medicine details Medicine name delafloxacin (Quofenix®) Formulation 300 mg powder for concentrate for solution for infusion; 450 mg tablet Reference number 4402 Indication Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered

2020 All Wales Medicines Strategy Group

7. Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo) - for the treatment of adults infected with HIV-1

Doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo) - for the treatment of adults infected with HIV-1 Final Appraisal Recommendation Advice No: 1020 – September 2020 Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo ® ) 100mg/300mg/245mg film-coated tablets Submission by Merck Sharp & Dohme Ltd Additional note(s): ? Please refer to the Summary of Product Characteristics section 4.4 (special warnings and precautions for use) and 5.1 (pharmacodynamic properties (...) . This recommendation has been ratified by Welsh Government and will be considered for review every three years. Recommendation of AWMSG Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo ® ) is recommended as an option for use within NHS Wales for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine, or tenofovir. This recommendation applies only in circumstances where the approved

2020 All Wales Medicines Strategy Group

8. Doravirine (Pifeltro) - for the treatment of adults infected with HIV-1

Doravirine (Pifeltro) - for the treatment of adults infected with HIV-1 Final Appraisal Recommendation Advice No: 0920 – September 2020 Doravirine (Pifeltro ® ) 100 mg film-coated tablets Submission by Merck Sharp & Dohme Ltd Additional note(s): ? Please refer to the Summary of Product Characteristics section 4.4 (special warnings and precautions for use) and 5.1 (pharmacodynamic properties) for further information, as specified in the licenced indication In reaching the above recommendation (...) three years. Recommendation of AWMSG Doravirine (Pifeltro ® ) is recommended as an option for use within NHS Wales, in combination with other antiretroviral products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the NNRTI class. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme (WPAS) is utilised or where the list/contract price is equivalent or lower than the WPAS price. Statement of use: No part

2020 All Wales Medicines Strategy Group

9. BHIVA guidelines on the management of opportunistic infection in people living with HIV: The clinical management of gastrointestinal opportunistic infections

; 2 Regional Infectious Diseases Unit, NHS Lothian, Edinburgh, UK; 3 Brighton and Sussex University Hospitals NHS Trust, Brighton, UK; 4 Mortimer Market Centre, Central and North West London NHS Foundation Trust, London, UK; 5 Tropical and Infectious Disease Unit, Royal Liverpool University Hospital (Liverpool University Hospitals Foundation Trust), Liverpool, UK E-mail: davidr.chadwick@nhs.net Keywords: colitis, diarrhoea, gastrointestinal opportunistic infection, oesophagitis 1 Methods The scope (...) is discussed in detail in a separate chapter of the BHIVA guidelines on the management of opportunistic infection in people living with HIV: The clinical management of Candidiasis 2019 [4]. 3.2 Other causes of oropharyngeal and oesophageal infections Oesophagitis should be suspected in patients who experience pain on swallowing, with or without symptoms of reflux or dysphagia. The other major HIV-related infectious causes of oesophagitis include herpes simplex virus (HSV) and cytomegalovirus (CMV

2020 British HIV Association

10. World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians

, managing, and treating hepatitis C virus infection. Clin Infect Dis . 2018 ;67:1477-1492. [PMID: ] doi: 5. Ghany MG , Morgan TR ; et al; . Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases–Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection. Hepatology . 2020 ;71:686-721. [PMID: ] doi: 6. Abraham GM , Spooner LM . Citius, altius, fortius: the new paradigm in the treatment of chronic hepatitis C (...) World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians World Health Organization Guidelines on Treatment of Hepatitis C Virus Infection: Best Practice Advice From the American College of Physicians | Annals of Internal Medicine LOGIN TO YOUR ACCOUNT or Create a new account Email Can't sign in? Forgot your password? Enter your email address below and we will send you the reset instructions Email

2020 American College of Physicians

11. Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) (Full text)

, Piacenza, Italy. 18 IInfectious Diseases Unit, Policlinico di Modena, Università Degli Studi di Modena e Reggio Emilia, Modena, Italy. 19 ILucia Diella Infectious Disease Unit - Department of Biomedical Sciences and Human Oncology, University of Bari, Policlinico di Bari, Italy. PMID: 32781244 PMCID: DOI: Free PMC article Item in Clipboard Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI (...) Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History

2020 EvidenceUpdates PubMed abstract

12. Clinical Features and Outcome of SARS-CoV-2 Infection in Neonates: A Systematic Review (Full text)

Clinical Features and Outcome of SARS-CoV-2 Infection in Neonates: A Systematic Review Clinical Features and Outcome of SARS-CoV-2 Infection in Neonates: A Systematic Review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation. Get the latest public health information from CDC: . Get (...) new results Optional text in email: Save Cancel Create a file for external citation management software Create file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Display options Display options Format Share Permalink Copy Page navigation J Trop Pediatr Actions . 2020 Aug 28;fmaa059. doi: 10.1093/tropej/fmaa059. Online ahead of print. Clinical Features and Outcome of SARS-CoV-2 Infection in Neonates: A Systematic Review

2020 EvidenceUpdates PubMed abstract

13. SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes (Full text)

Health, Westbury on Trym, UK. 8 Institute of Metabolism and Systems Research, WHO Collaborating Centre for Women's Health, University of Birmingham, Birmingham, UK. 9 Paediatric Infectious Diseases Research Group and Vaccine Institute, Institute of Infection and Immunity, St George's University of London, London, UK. 10 Immunisation and Countermeasures Division, Public Health England, UK. 11 British Paediatric Surveillance Unit, Royal College of Pediatrics and Child Health, UK. 12 School of Life (...) SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes SARS-CoV-2 infection in pregnancy: A systematic review and meta-analysis of clinical features and pregnancy outcomes - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving situation

2020 EvidenceUpdates PubMed abstract

14. Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: A systematic review (Full text)

Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: A systematic review Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: A systematic review - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced (...) 24. doi: 10.1002/ijgo.13329. Online ahead of print. Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: A systematic review , , , , , Affiliations Expand Affiliations 1 Department of Obstetrics and Gynecology, Royal Free Hospital NHS Trust, London, UK. 2 EGA Institute for Women's Health, University College London, London, UK. 3 National Heart and Lung Institute, Imperial College London, London, UK. 4 Barts

2020 EvidenceUpdates PubMed abstract

15. Infection prevention and control and surveillance for coronavirus disease (COVID-19) in prisons in EU/EEA countries and the UK

Infection prevention and control and surveillance for coronavirus disease (COVID-19) in prisons in EU/EEA countries and the UK Infection prevention and control and surveillance for coronavirus disease (COVID-19) in prisons in EU/EEA countries and the UK Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search Infection prevention and control and surveillance for coronavirus (...) disease (COVID-19) in prisons in EU/EEA countries and the UK Infection prevention and control and surveillance for coronavirus disease (COVID-19) in prisons in EU/EEA countries and the UK Technical report 3 Jul 2020 Cite: European Centre for Disease Prevention and Control Infection prevention and control and surveillance for coronavirus disease (COVID-19) in prisons in EU/EEA countries and the UK – July 2020. ECDC: Stockholm; 2020. This document provides principles of surveillance, infection

2020 European Centre for Disease Prevention and Control - Technical Guidance

16. Evidence summary for duration of infectiousness of SARS-CoV-2

summary for the duration of infectiousness in those that test positive for SARS-CoV-2 RNA Key points ? Public health interventions aim to minimise the burden of COVID-19 by reducing the spread of SARS-CoV-2. Important interventions that may be associated with specific durations of time include ‘isolation’ and ‘restriction of movements’. ? Isolation (or self-isolation) is defined as separating those with symptoms of, or diagnosed with COVID-19, from people who are not infected. ? Isolation is distinct (...) inform the duration of isolation required for patients who test positive for SARS-CoV-2 RNA. ? Viral culture studies measure the ability of SARS-CoV-2 to replicate in cultured cells. While a positive viral culture indicates potential infectiousness, risk of transmission (clinical infectivity) is also influenced by the viral titre, clinical and environmental factors, and behaviour of the infected individual. ? Contact tracing studies measure virus transmission between index cases (the first identified

2020 Health Information and Quality Authority

17. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19

, in particular any use of the guidelines in any software product. Executive Summary Coronavirus disease 2019 (COVID-19) is a pandemic with a rapidly increasing incidence of infections and deaths. Many pharmacologic therapies are being used or considered for treatment. Given the rapidity of emerging literature, the Infectious Diseases Society of America (IDSA) identified the need to develop living, frequently updated evidence-based guidelines to support patients, clinicians and other health-care professionals (...) Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Last updated September 25, 2020 and posted online at www.idsociety.org/COVID19guidelines. Please check website for most updated version of these guidelines. Version 3.3.0 Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Authors Adarsh Bhimraj 1 , Rebecca L. Morgan 2 , Amy Hirsch Shumaker 3 , Valery Lavergne 4 , Lindsey Baden 5

2020 Infectious Diseases Society of America

18. Rapid Review Update 3: What is known on the potential for COVID-19 re-infection, including new transmission after recovery?

individuals re-detected with SARS-CoV-2 or other human coronaviruses are infectious to others, but 5 studies explored whether close contacts of re-positive cases became infected. No cases of onward transmission were reported. Moderate Low Update 3: September 28, 2020 11 Park, M., Pawliuk, C., Nguyen, T., Griffitt, A., Dix-Cooper, L., Fourik, N., & Dawes, M. (2020). Determining the period of communicability of SARS-CoV-2: A rapid review of the literature. Preprint. Jul 30, 2020 (Search completed Jul 1 (...) , 2020) The objective of this rapid review was to identify the reported communicable period of the virus causing COVID-19 infection. The median length of time until viral clearance across all viral isolation studies (looking at when live virus could be cultured from samples) was 9 days, with a maximum of 32 days. The median length of time until viral clearance for viral shedding (when virus can still be detected in RT-PCR tests, but is not necessarily viable) was 24 days, with a maximum of 95 days

2020 COVID-19 Rapid Evidence Service

19. Infection prevention and control and preparedness for COVID-19 in healthcare settings - fifth update

Infection prevention and control and preparedness for COVID-19 in healthcare settings - fifth update Infection prevention and control and preparedness for COVID-19 in healthcare settings - fifth update Global Navigation Other sites: European Centre for Disease Prevention and Control An agency of the European Union Main Navigation Secondary Navigation Search Search Search Search Infection prevention and control and preparedness for COVID-19 in healthcare settings - fifth update Infection (...) prevention and control and preparedness for COVID-19 in healthcare settings - fifth update Technical report 6 Oct 2020 Cite: European Centre for Disease Prevention and Control. Infection prevention and control and preparedness for COVID-19 in healthcare settings – Fifth update. 6 October 2020. ECDC: Stockholm; 2020. This document aims to provide guidance to healthcare facilities and healthcare providers in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) on preparedness

2020 European Centre for Disease Prevention and Control - Technical Guidance

20. COVID-19: guidance for households with possible coronavirus infection

COVID-19: guidance for households with possible coronavirus infection COVID-19: guidance for households with possible coronavirus infection - GOV.UK Tell us whether you accept cookies We use about how you use GOV.UK. We use this information to make the website work as well as possible and improve government services. Accept all cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance and support Guidance COVID-19: guidance for households with possible coronavirus infection (...) Stay at home guidance for households with possible coronavirus (COVID-19) infection. Published 12 March 2020 Last updated 20 September 2020 — From: Documents HTML HTML Ref: PHE publications gateway number GW-1342 . Please tell us what format you need. It will help us if you say what assistive technology you use. . Please tell us what format you need. It will help us if you say what assistive technology you use. . Please tell us what format you need. It will help us if you say what assistive

2020 Public Health England